Loading...
Anti-CD19 chimeric antigen receptor (CAR) T-cell agents are an established treatment for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Investigators report an industry-sponsored, multinational, phase 1b–2 trial of a novel CAR T-cell therapy containing a modified anti-CD19 binding domain designed to decrease cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity (ICANS) and to enhance CAR T-cell engraftment and persistence. Adults with R/R B-ALL received a split dose of obecabtagene autoleucel (obe-cel) infusion based on bone marrow tumor cell burden prior to the administration of lymphodepleting chemotherapy.
Of 153 patients, 146 (95%) had successful CAR T-cell manufacture and 127 received…